Technology Opportunities

Refine / Revise Search41 technologies found
page 1 of 3
A method for induction of immune-regulatory properties on mesenchymal stem cells to be used for cell therapy (Hadasit)
Need: Many pathological conditions arise from dysregulation of the immune system. In autoimmune diseases, Graft-versus-Host Disease (GVHD) and transplanted organ rejection, the increased pathological activity of immune system cells damages bodily / transplanted tissues with outcomes that can be ...
Scientific Contact: Reuven Or
More Details...
A naturally-occurring peptide as a potential treatment for cancer (Hadasit)
　 Need: Metastases to liver are very common for primary breast, lung, and colorectal tumors, with a 5-year survival rate as low as <5%. Synchronous hepatic metastases may be identified in 10-20% of patients with colorectal cancer and up to 50% of those with some other extrahepatic ...
Scientific Contact: Rinat Abramovitch
More Details...
A Novel Flow Cytometry Tool for Fibrosis Scoring Through Hepatic Stellate Cell Differentiation (Hadasit)
Need: Nonalcoholic steatohepatitis (NASH) is a leading cause of morbidity and mortality with no effective therapy. However, there are numerous NASH drugs in clinical development, with a projected market during the 2020s of >$10B. The prevalence of NASH is ~7% worldwide and growing based on ...
Scientific Contact: Rifaat Safadi
More Details...
AlgoShield: preventing hernia mesh adhesions (Hadasit)
Need: Postoperative adhesions (fibrous bands of scar tissue) frequently occur following abdominal surgery and are a leading cause of intestinal obstruction. It has been estimated that more than 90% of patients who undergo abdominal operations will develop postoperative adhesions. The most ...
Scientific Contact: Yoav Mintz
More Details...
Allogeneic Tumor Cell Vaccination (Hadasit)
Need:Novel approaches for cancer management for adavnced stage melanoma patients are a significant unmet clinical need. Innovation:A Novel tool for active immunization of cancer patients by using modified tumor cell lines expressing MHC-I and co-stimulatory molecules. Findings: The cell ...
Scientific Contact: Michal Lotem
More Details...
An artemisinin derivative for the Treatment of CMV Viral Infections. (Hadasit)
Need: Novel approach for the treatment of Cytomegalovirus (CMV) infection. The technology addresses unmet medical need in the field of CMV management. The use of currently available anti-CMV drugs is limited due to toxicity, low oral bioavailability and drug resistance. Innovation:We have a ...
Scientific Contact: Dana Wolf
More Details...
AN INHALED FORMULATION OF FDA-APPROVED DRUGS FOR TREATMENT OF ARDS (Hadasit)
Prof. Rifaat Safadi and his team are developing an inhaled formulation that combines two FDA-approved drugs, which recruit and activate certain types of immune cells in patients with Acute Respiratory Distress Syndrome (ARDS). The inhaled formulation will enable a safer use of the drugs ...
Scientific Contact: Rifaat Safadi
More Details...
Anti Biofilm for the Treatment of Acne Vulgaris and Increased Susceptibility of Certain Bacterial Strains For Antibiotics (Hadasit)
Need: The market for acne drugs, largely based on 3 drugs and mostly cosmetic in purpose, is >$3B and forecast to grow to >$5B next decade. These numbers may be underestimates based on the psychological impact of disease and reticence to discuss it as well as use of antibiotics that is ...
Scientific Contact: David Enk
More Details...
Aortic Pacemaker (Hadasit)
Need: Heart failure is a major cause of death and disability in both developed and developing countries. Major clinical conditions associated with heart failure include: 1) End-stage chronic heart failure (including ischemic and non-ischemic cardiomyopathy), 2) Acute decompensated heart ...
Scientific Contact: David Planer
More Details...
Bolus Propagation Esophagography (BPE) (Hadasit)
Need: Chronic untreated Gastroesophageal Reflux (GERD) can cause serious complications. Inflammation of the esophagus from refluxed stomach acid can damage the lining and cause bleeding or ulcers (esophagitis). Scars from tissue damage can lead to narrowing of the esophagus (strictures) and ...
Scientific Contact: Azaria Rein
More Details...
Circulating microRNAs as Biomarkers for B-Cell Depletion Therapy/ Rituximab in Neuromyelitis Optica (Hadasit)
Need:Neuromyelitis optica (NMO) is a chronic autoimmune disease of the central nervous system (CNS). The main immunological feature of the disease is the presence of autoantibodies to Aquaporin 4 (AQP4+), identified in about 82% of cases. Currently, there are no reliable biomarkers for ...
Scientific Contact: Adi Vaknin
More Details...
Clinical Grade Embryonic Stem Cells for Multiple Indications (Hadasit)
Need Human embryonic stem cells (hESCs) can potentially proliferate indefinitely and can differentiate into any cell type. hESCs are expected to serve as an unlimited source of donor cells for many applications in regenerative medicine and have great potential for pharmaceutical research, ...
Scientific Contact: Benjamin Reubinoff
More Details...
CT Perfusion Reference Phantom (Hadasit)
Need: It is of extreme importance to monitor non-invasively the effect of anti-cancer therapy on tumors. Proliferation of cancer cells causes angiogenesis that increase the perfusion to the tissue. Radiotherapy, chemotherapy or thermotherapy can cause death or damage to the cells and decrease ...
Scientific Contact: Yacov Sosna
More Details...
Decoy Oligonucleotides Corresponding to NF-KappaB Binding Site in MGMT Promoter for Cancer Treatment and Drug Resistance. (Hadasit)
Need: There is a substantial unmet need for novel anti-drug-resistant cancer treatment. Alkylating agents (A certain type of chemotherapy) are the most widely used anti-cancer drugs. Drug resistance is a common obstacle for their use in cancer patients. Specifically, patients diagnosed with ...
Scientific Contact: Iris Lavon
More Details...
Erlotonib analogues for the noninvasive identification of EGFR tyrosine kinase inhibitor-responsive non-small cell lung carcinoma tumors using positron emission tomography (Hadasit)
Unmet Need: Activating mutations in the tyrosine kinase (TK) domain of the EGFR are detected in 10% to 30% of NSCLC patients, and evidence of their presence is a prerequisite for initiation of first-line therapy with selective TK inhibitors (TKIs), such as gefitinib and erlotinib. To date, ...
Scientific Contact: Eyal Mishani
More Details...
Hepatoprotective effect of alpha 1 anti trypsin (Hadasit)
Need: Protection of liver function and physiology during the course of a range of acute or chronic liver diseases, which include viral, bacterial, parasitic, immune-mediated, fatty liver, metabolic syndrome, diabetes, and atherosclerosis. A liver-supportive therapy as adjunct to other more ...
Scientific Contact: Yaron Ilan
More Details...
HIGH-THROUGHPUT TEST FOR SARS-COVID-2 VIRUS IN PATIENT SAMPLES (Hadasit)
The current test for SARS-CoV-2 virus requires several laborious steps as-well-as unique reagents that are at high demand these days. This project of Prof. Dana Wolf, in collaboration with Nir Fridman and Naomi Habib, is geared to use high-throughput sequencing methods for testing patient ...
Scientific Contact: Dana Wolf
More Details...
Human Stem Cell-Derived Neural Precursors for Treatment of CNS Autoimmune Disease. (Hadasit)
Unmet need: CNS-related autoimmune diseases like multiple sclerosis (MS) pose a great challenge for treatment for a large part of the world and are in need for novel therapies. Innovation: Use of human stem cells (HSCs) for the production of neuronal precursors for the treatment of autoimmune ...
Scientific Contact: Benjamin Reubinoff
More Details...
Icough - ACCUMULATIVE BREATH COUGHER (Hadasit)
95% of COVID-19 patient are “mild patient” and could be treated at home setting. More than 97% present respiratory symptoms. All hospitalization are caused by respiratory deterioration. Today, remote monitoring of systemic parameters (saturation, heartbeat, body temperature) provide ...
Scientific Contact: Tomer Batash
More Details...
Inhibition of Ornithine Aminotransferase for Treatment of Hepatocellular Carcinoma. (Hadasit)
Need:Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third leading cause of cancer mortality worldwide. Surgical resection and liver transplantation are considered the only cures for HCC, but benefit only 10-15% of patients. There is a growing need for the development of ...
Scientific Contact: Yaron Ilan
More Details...
ITTN's partners are affiliated with some of the world's leading Educational and Research Institutions.